TISOTUMAB VEDOTIN VS INVESTIGATOR'S CHOICE CHEMOTHERAPY IN SECOND- OR THIRD-LINE RECURRENT OR METASTATIC CERVICAL CANCER (INNOVATV 301/ENGOT-CX12/GOG-3057, TRIAL IN PROGRESS)

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER(2021)

引用 1|浏览6
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要